The federal government’s April 2026 rescheduling of marijuana signals a shift in how the U.S. approaches controlled substances, though the order does not directly affect psychedelic drugs like psilocybin, MDMA, and ibogaine, which remain Schedule I substances. However, the rescheduling demonstrates that the federal government can move substances out of Schedule I when evidence and public opinion support the decision, establishing a proof of concept for future drug policy reforms.
Acting Attorney General Todd Blanche achieved marijuana rescheduling under 21 U.S.C. § 811(d)(1), invoking the Single Convention on Narcotic Drugs and bypassing the Administrative Procedure Act’s standard notice-and-comment rulemaking procedures. This legal pathway creates distinct implications for psychedelics, as the Single Convention was scoped specifically to cannabis, coca, and opium-like drugs. Psychedelics are instead governed by a separate 1971 Convention on Psychotropic Substances, which was signed in February 1971 and entered into force in 1976—after the October 27, 1970 cutoff date that governs the treaty authority used for marijuana rescheduling.
Psychedelic rescheduling would likely proceed through the standard Section 811(a)/(b) process using Health and Human Services scientific findings and Administrative Procedure Act rulemaking, a slower but potentially more durable legal foundation. The marijuana rescheduling record now establishes important precedent on therapeutic benefit, appropriate scheduling criteria, and the inadequacy of Schedule I for substances with accepted medical applications. For psychedelics, the FDA’s Breakthrough Therapy designations for psilocybin and MDMA—which require preliminary clinical evidence of substantial improvement over existing therapies—represent meaningful early markers building toward a future HHS evaluation.
State-level psychedelic programs in Oregon and Colorado, where trained facilitators administer psilocybin in regulated service centers, could generate real-world evidence on safety and therapeutic outcomes comparable to what state medical marijuana programs provided to support the 2026 rescheduling decision. The April 2026 executive order allocated $50 million in federal support for state psychedelic programs and established a conditional rescheduling pipeline when a Schedule I substance completes Phase 3 trials for a serious mental health disorder.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://natlawreview.com/article/what-marijuana-rescheduling-order-means-psychedelics